Tag Archives: bladder cancer

Study Reveals Cancer-Detection Dogs Can Accurately Identify Bladder Cancer in Other Dogs

(IN BRIEF) A study led by the University of Bristol and published in Veterinary and Comparative Oncology has demonstrated that trained dogs can accurately detect bladder cancer in other dogs through urine samples. Using a non-invasive method, the dogs achieved … Read the full press release

AstraZeneca’s Imfinzi Granted Priority Review by FDA for Groundbreaking Perioperative Immunotherapy in Bladder Cancer

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), potentially becoming the first perioperative immunotherapy in this curative-intent setting. Supported by results from the NIAGARA Phase III trial, … Read the full press release

GUSTO Trial Aims to Revolutionize Bladder Cancer Treatment with Genetic Tailoring

(IN BRIEF) A groundbreaking trial called GUSTO, led jointly by the University of Southampton, Sheffield Teaching Hospitals NHS Foundation Trust, and the University of Leeds, has been launched to potentially revolutionize bladder cancer treatment by matching therapies to the genetic … Read the full press release

AstraZeneca’s Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option

(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release

FDA Approves Roche’s TECENTRIQ as initial treatment for certain advanced bladder cancer patients

First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) … Read the full press release